NEWAMSTERDAM PHARMA CO NV (NAMS)
NL00150012L7 - Common Stock
We assign a fundamental rating of 2 out of 10 to NAMS. NAMS was compared to 565 industry peers in the Biotechnology industry. While NAMS seems to be doing ok healthwise, there are quite some concerns on its profitability. NAMS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year NAMS has reported negative net income.
1.2 Ratios
The Return On Assets of NAMS (-16.57%) is better than 82.00% of its industry peers.
NAMS has a Return On Equity of -18.48%. This is amongst the best in the industry. NAMS outperforms 86.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.57% | ||
| ROE | -18.48% | ||
| ROIC | N/A |
ROA(3y)-3.89%
ROA(5y)N/A
ROE(3y)-4.3%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NAMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NAMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
NAMS has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, NAMS has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 23.26 indicates that NAMS is not in any danger for bankruptcy at the moment.
NAMS has a better Altman-Z score (23.26) than 94.30% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that NAMS is not too dependend on debt financing.
NAMS has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 23.26 |
ROIC/WACCN/A
WACC7.18%
2.3 Liquidity
NAMS has a Current Ratio of 10.15. This indicates that NAMS is financially healthy and has no problem in meeting its short term obligations.
NAMS has a better Current ratio (10.15) than 81.64% of its industry peers.
NAMS has a Quick Ratio of 10.15. This indicates that NAMS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.15, NAMS belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.15 | ||
| Quick Ratio | 10.15 |
3. Growth
3.1 Past
NAMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -505.51%.
EPS 1Y (TTM)-505.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1283.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -49.87% on average over the next years. This is quite bad
NAMS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.29% yearly.
EPS Next Y-1306.89%
EPS Next 2Y-285.38%
EPS Next 3Y-132.19%
EPS Next 5Y-49.87%
Revenue Next Year-87.36%
Revenue Next 2Y-64.73%
Revenue Next 3Y-60.45%
Revenue Next 5Y3.29%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
NAMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NAMS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as NAMS's earnings are expected to decrease with -132.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-285.38%
EPS Next 3Y-132.19%
5. Dividend
5.1 Amount
NAMS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEWAMSTERDAM PHARMA CO NV
NASDAQ:NAMS (11/20/2024, 8:00:01 PM)
Premarket: 19.99 -0.02 (-0.1%)20.01
-3.67 (-15.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.85B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.57% | ||
| ROE | -18.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.15 | ||
| Quick Ratio | 10.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-505.51%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-1306.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y